Key result
NTSR1 G301R variant is linked to ~51% lower risk of switching from ACE inhibitors.
Why the study?
Up to half of patients switch or discontinue antihypertensives within the first year, but the underlying mechanisms remain elusive.
Do specific genetic variants predict antihypertensive medication switching or discontinuation within the first year in genotyped patients?
Cohort (n=400,000)
Yes
Do specific genetic variants predict antihypertensive medication switching or discontinuation within the first year in genotyped patients?
Genetic variants in the neurotensin-NTSR1 pathway and CYP3A4*22 predict switching from ACE inhibitors and dihydropyridine calcium channel blockers, respectively, highlighting potential for genotype-guided prescribing.
Answers are grounded in this paper and cite their sources.
Genetic predictors of antihypertensive trajectories identified; leaves open whether they can guide adherence interventions in practice.
BACKGROUND AND AIMS: Up to half of patients switch or discontinue antihypertensive medications within the first year, but underlying mechanisms remain elusive. This study aimed to identify genetic predictors of antihypertensive medication use trajectories within the first year. METHODS: Using longitudinal medication data from >400 000 genotyped antihypertensive medication users across three cohorts (FinnGen, the UK Biobank, and the Estonian Biobank), short-term antihypertensive medication use trajectories were classified as Continue, Switch, or Discontinue. Genome-wide association studies were performed across five medication classes. RESULTS: In total, 14 genome-wide significant loci were identified for switching from angiotensin-converting enzyme inhibitors (ACEI) and dihydropyridine calcium channel blockers (dCCB) to other antihypertensive medications. For ACEI switching, evidence converged on the neurotensin-NTSR1 pathway, including a 320-fold Finnish-enriched protective missense variant in the neurotensin receptor gene NTSR1 (rs148569146 [G301R], odds ratio [OR] 0.49, P = 3.3 × 10-43) and a variant near RASSF9 (rs181941187, OR = 0.74, P = 1.2 × 10-49) tagging the neurotensin gene NTS. In drug-gene interaction analyses, NTSR1 G301R was associated with reduced ACEI-induced cough risk (OR 0.39, P = 8.1 × 10-4). The dCCB switching locus at CYP3A43 was in near-complete linkage (r2 = 0.99) with the functional CYP3A4*22 allele (rs35599367, OR 1.23, P = 6.1 × 10-10). A polygenic risk score (PRS) for ACEI switching predicted two-fold ACEI cough risk in the top 10% PRS compared with the middle 20% in an independent sample of the Estonian Biobank. CONCLUSIONS: These findings extend the bradykinin hypothesis of ACEI-induced cough by implicating neurotensin-NTSR1 signalling, pinpoint CYP3A4*22 as a novel functional predictor of dCCB switching with potential for genotype-guided prescribing, and validate medication use trajectories as a framework for pharmacogenetic discovery.
No takes yet. Share an insight, caveat, or question.
Vaura et al. (2026) conducted a cohort in Hypertension (n=400,000). Genetic variants (e.g., NTSR1 G301R, CYP3A4*22) vs. Non-carriers was evaluated on Switching from angiotensin-converting enzyme inhibitors (ACEI) to other antihypertensive medications (OR 0.49, p=3.3 × 10-43). The NTSR1 G301R missense variant was associated with a reduced risk of switching from ACE inhibitors and reduced ACEI-induced cough risk.
Synapse has enriched 10 related papers. Consider them for comparative context: